Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00766116 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) (NCT00766116)

Trial Description
This study will test an experimental combination of the drugs gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories), an antibody-drug conjugate, and Azacitidine (Vidaza®; Celgene) in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia (AML) that has come back after treatment.

This trial is sponsored by The University of California, San DiegoCelgene Co./ Pfizer. [1]

Study Data

  • Condition: Acute Myeloid Leukemia
  • Interventions:
  • Phase: I & II
  • Estimated Enrollment: 36
  • Start: July 2005
  • Estimated Completion: February 2015
  • Last verified: October 2014

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 20, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar